Is It Time to Move Beyond Graft-Versus-Host Disease-Free, Relapse-Free Survival as a Primary End Point in Clinical Trials for Hematopoietic Cell Transplantation?

A Amar H. Kelkar (Department of Medical Oncology, Dana–Farber Cancer Institute, Boston) G Gregory A. Abel (Dana-Farber Cancer Institute, Boston, Massachusetts, United States) C Corey S. Cutler (7Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA) S Stephanie J. Lee R Robert J. Soiffer (Dana-Farber Cancer Institute)

Article Details

Volume / Issue Vol. 44, Issue 15
Published May 20, 2026
Pages 1389-1394
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (5)

A

Amar H. Kelkar

Department of Medical Oncology, Dana–Farber Cancer Institute, Boston

G

Gregory A. Abel

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

C

Corey S. Cutler

7Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

S

Stephanie J. Lee

R

Robert J. Soiffer

Dana-Farber Cancer Institute